LD50=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.
A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Hydrocodone | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Magnesium sulfate | The therapeutic efficacy of Levorphanol can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Levorphanol may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Orphenadrine | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Pramipexole | Levorphanol may increase the sedative activities of Pramipexole. |
| Ropinirole | Levorphanol may increase the sedative activities of Ropinirole. |
| Rotigotine | Levorphanol may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Levorphanol. |
| Sodium oxybate | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Thalidomide | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Levorphanol is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Levorphanol is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Levorphanol. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Levorphanol. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Levorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levorphanol. |
| Naltrexone | The therapeutic efficacy of Levorphanol can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Levorphanol. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Levorphanol is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Levorphanol is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Levorphanol is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Diamorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Levorphanol is combined with Bezitramide. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Levorphanol is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Levorphanol is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Levorphanol is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Levorphanol is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Levorphanol is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Levorphanol is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Levorphanol is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Levorphanol can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Levorphanol is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Levorphanol is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Naloxegol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Levorphanol is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levorphanol. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Levorphanol. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Levorphanol. |
| Mirtazapine | Levorphanol may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Levorphanol. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Alaproclate. |
| Ethanol | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol. |
| Phentermine | Phentermine may increase the analgesic activities of Levorphanol. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Levorphanol. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Levorphanol. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Levorphanol. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Levorphanol. |
| MMDA | MMDA may increase the analgesic activities of Levorphanol. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Levorphanol. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Levorphanol. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levorphanol. |